Thrivent Financial for Lutherans Purchases 4,365 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Thrivent Financial for Lutherans raised its position in Axon Enterprise, Inc. (NASDAQ:AXON) by 1.6% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 270,430 shares of the biotechnology company’s stock after acquiring an additional 4,365 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Axon Enterprise were worth $79,571,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. ICA Group Wealth Management LLC purchased a new stake in shares of Axon Enterprise during the 4th quarter valued at about $26,000. Blue Trust Inc. grew its position in Axon Enterprise by 987.5% during the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 79 shares during the period. Trivant Custom Portfolio Group LLC bought a new stake in Axon Enterprise during the first quarter valued at approximately $31,000. First PREMIER Bank purchased a new stake in Axon Enterprise during the first quarter valued at approximately $33,000. Finally, Rise Advisors LLC raised its position in Axon Enterprise by 49.0% in the first quarter. Rise Advisors LLC now owns 143 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 47 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $380.99, for a total transaction of $380,990.00. Following the completion of the transaction, the director now owns 27,259 shares in the company, valued at approximately $10,385,406.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Axon Enterprise news, Director Michael Garnreiter sold 1,000 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $380.99, for a total transaction of $380,990.00. Following the completion of the transaction, the director now owns 27,259 shares in the company, valued at $10,385,406.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Brittany Bagley sold 4,338 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the completion of the sale, the chief financial officer now owns 98,825 shares in the company, valued at $37,449,733.75. The disclosure for this sale can be found here. Over the last three months, insiders have sold 317,981 shares of company stock worth $115,662,734. Corporate insiders own 6.10% of the company’s stock.

Axon Enterprise Price Performance

AXON stock opened at $393.29 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. The company’s fifty day moving average price is $348.04 and its 200-day moving average price is $317.22. Axon Enterprise, Inc. has a one year low of $189.12 and a one year high of $393.58. The company has a market capitalization of $29.68 billion, a PE ratio of 115.00, a price-to-earnings-growth ratio of 10.34 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $1.02 by $0.18. The business had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The business’s quarterly revenue was up 34.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.80 EPS. On average, equities analysts anticipate that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AXON has been the subject of several analyst reports. Bank of America started coverage on Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price objective for the company. JMP Securities upped their price target on Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Jefferies Financial Group assumed coverage on Axon Enterprise in a research report on Wednesday, July 17th. They set a “buy” rating and a $385.00 price objective on the stock. Robert W. Baird increased their target price on shares of Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Finally, Barclays lifted their price target on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, Axon Enterprise presently has an average rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.